Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2022 Apr 11

PMID 35400994

Authors

Rongxiu Huo

Qianyu Guo

Junping Hu

Na Li

Rui Gao

Liangyu Mi

Zhaoliang Zhang

Hechao Liu

Zhiying Guo

Hanxi Zhao

Liyun Zhang

Ke Xu

Affiliations

Soon will be listed here.

Abstract

Interstitial lung disease (ILD) refers to a heterogeneous group of diseases characterized by lung fibroblast proliferation, interstitial inflammation, and fibrosis-induced lung damage. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is known to be activated by pro-fibrotic/pro-inflammatory cytokines such as IL-6 and IL-13, whose levels are elevated in ILD. The overexpression of growth factors such as transforming growth factor β1 in ILD activates the JAK/STAT pathway through classical or non-classical pathways, promotes macrophage activation, increases the release of pro-inflammatory and pro-fibrosis factors, and facilitates fibroblast differentiation into myofibroblasts. These findings implicate that the JAK/STAT pathway plays an important role in the course of ILD. Recent evidence also suggests that JAK inhibition alleviates excessive inflammation and pulmonary fibrosis. Accordingly, the JAK inhibitors may serve as promising drugs for the treatment of JAK/STAT-induced ILD.

Citing Articles

Anti-PL-7/PL-12 antisynthetase syndrome associated with interstitial lung disease following SARS-COV-2 infection and vaccination: A case study review.

Garcia-Bravo L, Villegas A, Lopez Uceda B, Mariscal A, Vadillo C, Nieto Barbero M Heliyon. 2025; 11(2):e41311.

PMID: 39906838 PMC: 11791273. DOI: 10.1016/j.heliyon.2024.e41311.

Successful treatment of rheumatoid arthritis-associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition.

Sunaga A, Inoue T Respirol Case Rep. 2024; 12(9):e70023.

PMID: 39253319 PMC: 11381312. DOI: 10.1002/rcr2.70023.

Highlights on Future Treatments of IPF: Clues and Pitfalls.

Libra A, Sciacca E, Muscato G, Sambataro G, Spicuzza L, Vancheri C Int J Mol Sci. 2024; 25(15).

PMID: 39125962 PMC: 11313529. DOI: 10.3390/ijms25158392.

Modulating lung fibroblast activation via senolysis of senescent human alveolar epithelial cells.

Spina J, Carr T, Phillips L, Knight H, Crosbie N, Lloyd S Aging (Albany NY). 2024; 16(13):10694-10723.

PMID: 38976646 PMC: 11272128. DOI: 10.18632/aging.205994.

Janus Kinase Inhibitors and Interstitial Lung Disease Associated With Pediatric Rheumatic Diseases: An Unexplored Field.

Sapountzi E, Fotis L, Kotanidou E, Fidani L, Galli-Tsinopoulou A Cureus. 2023; 15(12):e50928.

PMID: 38143732 PMC: 10739229. DOI: 10.7759/cureus.50928.

References

Li M, Luan F, Zhao Y, Hao H, Zhou Y, Han W . Epithelial-mesenchymal transition: An emerging target in tissue fibrosis. Exp Biol Med (Maywood). 2015; 241(1):1-13. PMC: 4935434. DOI: 10.1177/1535370215597194. View

Silva-Carmona M, Vogel T, Marchal S, Guesmi M, Dubus J, Leroy S . Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors. Am J Respir Crit Care Med. 2020; 202(6):893-897. DOI: 10.1164/rccm.201906-1204LE. View

Milara J, Hernandez G, Ballester B, Morell A, Roger I, Montero P . The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018; 19(1):24. PMC: 5801676. DOI: 10.1186/s12931-018-0728-9. View

Chen Z, Wang X, Ye S . Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med. 2019; 381(3):291-293. DOI: 10.1056/NEJMc1900045. View

Bousoik E, Montazeri Aliabadi H . "Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling Pathway. Front Oncol. 2018; 8:287. PMC: 6079274. DOI: 10.3389/fonc.2018.00287. View

Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T . Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018; 57(12):2114-2119. DOI: 10.1093/rheumatology/key188. View

Pechkovsky D, Prele C, Wong J, Hogaboam C, McAnulty R, Laurent G . STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF. Am J Pathol. 2012; 180(4):1398-412. DOI: 10.1016/j.ajpath.2011.12.022. View

Hornig J, Weinhage T, Schmidt L, Buerke B, Schneider U, Pavenstadt H . [Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment]. Z Rheumatol. 2018; 77(10):952-957. DOI: 10.1007/s00393-018-0565-8. View

Mikolasch T, Garthwaite H, Porter J . Update in diagnosis and management of interstitial lung disease . Clin Med (Lond). 2017; 17(2):146-153. PMC: 6297625. DOI: 10.7861/clinmedicine.17-2-146. View

10.

Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N . The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008; 10(10):1199-207. DOI: 10.1038/ncb1780. View

11.

Sendo S, Saegusa J, Yamada H, Nishimura K, Morinobu A . Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice. Arthritis Res Ther. 2019; 21(1):184. PMC: 6685227. DOI: 10.1186/s13075-019-1963-2. View

12.

Subramaniam P, Torres B, Johnson H . So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine. 2001; 15(4):175-87. DOI: 10.1006/cyto.2001.0905. View

13.

Ma X, Chen R, Liu X, Xie J, Si K, Duan L . Effects of matrine on JAK-STAT signaling transduction pathways in bleomycin-induced pulmonary fibrosis. Afr J Tradit Complement Altern Med. 2013; 10(3):442-8. PMC: 3777585. DOI: 10.4314/ajtcam.v10i3.10. View

14.

Fan X, Wang Z, Li Z . STAT1 activation and STAT1-dependent immune-response gene ICAM-1 expression in alveolar macrophages of rats suffered from interstitial pulmonary fibrosis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2004; 19(1):3-6. View

15.

Balci S, Kisla Ekinci R, de Jesus A, Goldbach-Mansky R, Yilmaz M . Baricitinib experience on STING-associated vasculopathy with onset in infancy: A representative case from Turkey. Clin Immunol. 2019; 212:108273. DOI: 10.1016/j.clim.2019.108273. View

16.

Owen K, Brockwell N, Parker B . JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers (Basel). 2019; 11(12). PMC: 6966445. DOI: 10.3390/cancers11122002. View

17.

Wang Y, Li Y, Wang X, Li X, Chen Y, Yang L . Effect of Total Flavonoids of Bunge on the Expression of p-JAK1-and p-STAT1-Related Proteins in Idiopathic Pulmonary Fibrosis. Evid Based Complement Alternat Med. 2020; 2020:2407239. PMC: 7474768. DOI: 10.1155/2020/2407239. View

18.

Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz D . JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017; 77(5):521-546. PMC: 7102286. DOI: 10.1007/s40265-017-0701-9. View

19.

Shieh J, Tseng H, Jung F, Yang S, Lin J . Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model. Mediators Inflamm. 2019; 2019:7947596. PMC: 6458868. DOI: 10.1155/2019/7947596. View

20.

Ma B, Li X . Resveratrol extracted from Chinese herbal medicines: A novel therapeutic strategy for lung diseases. Chin Herb Med. 2020; 12(4):349-358. PMC: 7498443. DOI: 10.1016/j.chmed.2020.07.003. View